Details

Autor(en) / Beteiligte

• Hogendorf, Adam S
• Hogendorf, Agata
• Kurczab, Rafał
• Kalinowska-Tłuścik, Justyna
• Popik, Piotr
• Nikiforuk, Agnieszka
• Krawczyk, Martyna
• Satała, Grzegorz
• Lenda, Tomasz
• Knutelska, Joanna
• Bugno, Ryszard
• Staroń, Jakub
• Pietruś, Wojciech
• Matłoka, Mikołaj
• Dubiel, Krzysztof
• Moszczyński-Pętkowski, Rafał
• Pieczykolan, Jerzy
• Wieczorek, Maciej
• Pilarski, Bogusław
• Zajdel, Paweł
• Bojarski, Andrzej J

Titel

2-Aminoimidazole-based antagonists of the 5-HT 6 receptor - A new concept in aminergic GPCR ligand design

Ist Teil von

• European journal of medicinal chemistry, 2019-06, Vol.179, p.1

Ort / Verlag

France

Erscheinungsjahr

2019

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• A new strategy in the design of aminergic GPCR ligands is proposed - the use of aromatic, heterocyclic basic moieties in place of the evergreen piperazine or alicyclic and aliphatic amines. This hypothesis has been tested using a benchmark series of 5-HT R antagonists obtained by coupling variously substituted 2-aminoimidazole moieties to the well established 1-benzenesulfonyl-1H-indoles, which served as the ligands cores. The crystallographic studies revealed that upon protonation, the 2-aminoimidazole fragment triggers a resonance driven conformational change leading to a form of higher affinity. This molecular switch may be responsible for the observed differences in 5-HT R activity of the studied chemotypes with different amine-like fragments. Considering the multiple functionalization sites of the embedded guanidine fragment, diverse libraries were constructed, and the relationships between the structure and activity, metabolic stability, and solubility were established. Compounds from the N-(1H-imidazol-2-yl)acylamide chemotype (10a-z) exhibited high affinity for 5-HT R and very high selectivity over 5-HT , 5-HT , 5-HT and D receptors (negligible binding), which was attributed to their very weak basicity. The lead compound in the series 4-methyl-5-[1-(naphthalene-1-sulfonyl)-1H-indol-3-yl]-1H-imidazol-2-amine (9i) was shown to reverse the cognitive impairment caused by the administration of scopolamine in rats indicating procognitive potential.